A metabolically stable analog of the anti-inflammatory endogenous CB, PEA; inhibits FAAH-mediated hydrolysis of AEA by 54% at a concentration of 100 µM; has weak CB receptor affinity, in that 100 µM inhibits agonist binding (1 nM CP 55,940 or WIN 55,212-2) only 26% and 15.5% at the human CB1 and CB2 receptors, respectively.